Clinical Trial Update: Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes. [Phase 2]

View source ↗

Summary

Pfizer conducted a Phase 2 trial to evaluate CP-778,875 on HDL-C in adults with dyslipidemia and type 2 diabetes. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Type 2 Diabetes Mellitus

Drugs mentioned

• CP-778,875

Snippet

Sponsor: Pfizer | Conditions: Dyslipidemia | Phase 2 | Status: COMPLETED